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vertebral, hip and wrist fracture or death (either natural or excess mortality due to 
fracture). Swedish data on fracture costs, utility reductions after fracture, fracture risks 
and mortality rates were used. Uncertainty was investigated using one-way and proba-
bilistic sensitivity analyses. Costs and utilities were discounted at annual discount rates 
of 3%. RESULTS: The analyzed cohort comprised patients aged 69 years (80% 
female) with a BMD T-Score of −2.5 SD and an historical vertebral fracture (5 years 
previous) and an incident vertebral fracture. In the base-case analysis of this cohort 
the costs in the teriparatide treatment group were 558,918 SEK per patient compared 
to 552,026 SEK in the no teriparatide group. The cost per QALY gained of teriparatide 
compared to no teriparatide was estimated to be SEK 25,000. The results were robust 
under a wide range of assumptions. CONCLUSIONS: For the analyzed cohorts, the 
base-case and one-way sensitivity analyses performed indicate that an 18-month 
teriparatide regimen versus no treatment in patients with glucocorticoid induced 
osteoporosis is cost-effective from the perspective of the Swedish payer.
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic, progressive, inﬂ ammatory 
disease that affects physical functioning and quality-of-life and is associated with 
premature mortality and substantial economic burden. We aimed to assess the cost-
effectiveness of tocilizumab added to disease-modifying antirheumatic drugs 
(DMARD) in patients with active RA despite DMARD therapy from the perspective 
of public health care system in Costa Rica. METHODS: A decision analysis was 
carried out to compare tocilizumab 8 mg/kg given every 4 weeks; inﬂ iximab 3 mg/kg 
(weeks 0, 2, 6, 14) and 5 mg/kg (every 8 weeks from week 22); etanercept 25 mg 
given twice a week and adalimumab 40 mg given every other week. The model 
included acquisition costs of biological agents during ﬁ rst year of treatment besides 
infusion-related costs for inﬂ iximab and tocilizumab. Indirect comparison techniques 
were needed to adjust American College of Rheumatology (ACR) responses rates 
found in 10 placebo-controlled clinical trials with biological agents used as add-on 
therapy to DMARD. ACR70 response rate, which can be regarded as a close measure 
of remission, was selected as primary efﬁ cacy outcome. Unitary costs were gathered 
from the 2010 Ofﬁ cial Price List of the Public Health Care System in Costa Rica. All 
costs are expressed in 2010 US dollars. RESULTS: First-year costs for an average 
70 kg weight patient were lower with tocilizumab (US$12,272) than with etanercept 
(US$13,000), adalimumab (US$13,650) and inﬂ iximab (US$14,340). Adjusted 
ACR70 response rate was higher for tocilizumab (26%) than for adalimumab (19%), 
etanercept (18%) and inﬂ iximab (12%). Incremental cost per patient achieving an 
ACR70 response with tocilizumab instead of anti-tumor necrosis factor (TNF) agents 
were estimated at −US$9,100, −US$14,771 and −US$19,686 for etanercept, adalim-
umab and inﬂ iximab, respectively. CONCLUSIONS: When used instead of anti-TNF 
agents, add-on treatment with tocilizumab brings both health beneﬁ ts and cost-savings 
for RA patients with inadequate response to previous DMARD therapy.
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OBJECTIVES: Abatacept in combination with MTX has recently been granted a 
positive opinion from the European Medicines Agency for use for the treatment of 
moderate to severe active rheumatoid arthritis in adult patients who responded inad-
equately to previous therapy with one or more conventional disease-modifying anti-
rheumatic drugs (cDMARDs) including methotrexate (MTX). This analysis explores 
the cost-effectiveness of abatacept in this new indication. METHODS: A patient-
simulation treatment-sequence economic model was constructed to estimate the incre-
mental cost per quality adjusted life-year (QALY) for patients with RA in the United 
Kingdom. Abatacept with MTX , followed by a sequence of DMARDs was compared 
against a sequence of cDMARDs. Treatment-speciﬁ c efﬁ cacy in terms of Health 
Assessment Questionnaire (HAQ) was used to calculate the patient’s utility medical 
resource use and cost over a lifetime. Mortality was HAQ dependent. The analysis is 
performed from a National Health Service. Costs and outcomes were discounted at 
3.5% each. RESULTS: Abatacept with MTX was estimated to yield 1.09 QALYs per 
patient (6.42 vs. 5.33) over lifetime, compared to DMARDs. The total lifetime costs 
associated with abatacept with MTX were £110,094 and total costs for cDMARDs 
were £79,933 resulting in an incremental cost-effectiveness ratio (ICER) of £27,657 
per QALY gained. Sensitivity analysis conﬁ rmed the robustness of the model ﬁ ndings. 
CONCLUSIONS: This study has demonstrated that abatacept with MTX is a cost-
effective treatment option compared to cDMARDs for patients with rheumatoid 
arthritis after an inadequate response to MTX.
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OBJECTIVES: About 30% of patients treated with an anti-TNF agent failed to 
achieve an improvement of 20% in American College of Rheumatology (ACR) 
response. Recent clinical practice guidelines recommend the use of rituximab after 
previous failure of one anti-TNF. This study aims to assess the cost-effectiveness of 
rituximab compared to cycling between anti-TNF agents in this population from the 
perspective of the public health care system in Mexico. METHODS: A decision analy-
sis was carried out to compare 2 rituximab courses (1 course, consisting of 2 infusions 
of 1 g each) given 6 months apart; inﬂ iximab 3 mg/kg (weeks 0, 2, 6, 14) and 5 mg/
kg (weeks 22, 30, 38 and 46); etanercept 25 mg twice a week and adalimumab 40 mg 
every other week. Only direct medical costs cumulated during a one-year timeframe 
were accounted for and these included acquisition cost of biologic drugs besides infu-
sion costs for rituximab and inﬂ iximab. Primary efﬁ cacy outcome was deﬁ ned as an 
improvement of 70% in ACR response (ACR70), which is a close measure of remis-
sion. Indirect comparison techniques were used to adjust ACR responses rates found 
in 9 clinical trials. Number needed to treat (NNT) to obtain an ACR70 was then 
calculated. All costs are reported in 2009 US dollars (USD). RESULTS: For a 70 Kg 
patient, annual mean costs were estimated at USD$13,025 for rituximab, USD$12,938 
for inﬂ iximab, USD$12,226 for adalimumab and USD$10,850 for etanercept. 
Adjusted ACR70 rates were higher in rituximab (12.4%) than in adalimumab (9.0%), 
etanercept (8.2%) and inﬂ iximab (5.4%). Average cost to achieve an ACR70 was 
lower with rituximab (USD$105,047) than with anti-TNF therapies, leading to savings 
of USD$27,270; USD$30,797 and USD$134,543 compared to etanercept, adalim-
umab and inﬂ iximab, respectively. CONCLUSIONS: This study suggests that ritux-
imab treatment after previous failure of one anti-TNF agent is a cost-effective strategy 
compared to cycling between anti-TNF agents.
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OBJECTIVES: About 30% of patients treated with an anti-TNF agent failed to 
achieve an improvement of 20% in American College of Rheumatology (ACR) 
response. Recent clinical practice guidelines recommend the use of rituximab after 
previous failure of one anti-TNF. This study aims to assess the cost-effectiveness of 
rituximab compared to cycling between anti-TNF agents in this population from the 
perspective of public health care system in Costa Rica. METHODS: A decision analy-
sis was carried out to compare 2 rituximab courses (1 course, consisting of 2 infusions 
of 1 g each) given 6 months apart; inﬂ iximab 3 mg/kg (weeks 0, 2, 6, 14) and 5 mg/
kg (weeks 22, 30, 38 and 46); etanercept 25 mg twice a week and adalimumab 40 mg 
every other week. Only direct medical costs cumulated during a one-year timeframe 
were accounted for and these included acquisition cost of biologic drugs besides infu-
sion costs for rituximab and inﬂ iximab. Primary efﬁ cacy outcome was deﬁ ned as an 
improvement of 70% in ACR response (ACR70), which is a close measure of remis-
sion. Indirect comparison techniques were used to adjust ACR responses rates found 
in 9 clinical trials. Number needed to treat (NNT) to obtain an ACR70 was then 
calculated. All costs are reported in 2009 US dollars (USD). RESULTS: For a 70 Kg 
patient, annual mean costs were estimated at US$15,040 for rituximab, US$14,340 
for inﬂ iximab, US$13,650 for adalimumab, and US$13,000 for etanercept. Adjusted 
ACR70 rates were higher in rituximab (12.4%) than in adalimumab (9.0%), etaner-
cept (8.2%) and inﬂ iximab (5.4%). Average cost to achieve an ACR70 was lower 
with rituximab (US$121,290) than with anti-TNF therapies, leading to savings of 
US$30,377; US$37,247; and US$144,266 compared to etanercept, adalimumab and 
inﬂ iximab, respectively. CONCLUSIONS: This study suggests that rituximab treat-
ment after previous failure of one anti-TNF agent is a cost-effective strategy compared 
to cycling between anti-TNF agents.
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OBJECTIVES: Denosumab represents a new therapeutic opportunity for the treatment 
of osteoporosis, that received a positive opinion from the European Committee for 
Medical Products for Human Use in December 2009. This study aims to evaluate the 
cost-effectiveness of denosumab compared with the most relevant alternative (i.e. 
generic alendronate) in the treatment of postmenopausal osteoporotic women. 
METHODS: The cost-effectiveness of treatment for 3-years with denosumab was 
compared with generic alendronate using an updated version of a previously validated 
Markov microsimulation model (Value Health 2009:12:687–96). The model was 
